Hygroton (Chlortalidone)

Chlortalidone blocks the sodium‑chloride cotransporter in the distal convoluted tubule of the kidney, decreasing reabsorption of sodium and chloride. This promotes the excretion of water and electrolytes, lowering blood volume and consequently reducing blood pressure.

The appropriate dose of Hygroton is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and laboratory results. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of chlortalidone in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Hygroton, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with classic thiazide diuretics, chlortalidone has a longer half‑life and a more potent diuretic effect, often allowing once‑daily dosing. It is frequently chosen when a stronger, sustained blood‑pressure‑lowering effect is needed, but individual response and tolerance vary.

Store Hygroton at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Hygroton is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should follow the specific instructions given by their prescriber to maintain consistent absorption.

Serious risks include severe electrolyte disturbances such as hyponatremia or hypokalemia, acute kidney injury, and rare allergic reactions like Stevens‑Johnson syndrome. Patients should be monitored regularly for these complications, especially during the initial phases of therapy.

Hygroton is contraindicated in patients with known hypersensitivity to chlortalidone or other sulfonamide‑derived drugs, in those with severe renal impairment, and in individuals with anuria. Clinicians should also exercise caution in patients with gout, diabetes, or hepatic disease.